Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC) Meeting Abstract
| Authors: | Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; Panageas, K.; Bluth, M. J.; Wong, P.; Wolchok, J. D.; Rosenberg, J. E.; Bajorin, D. F.; Callahan, M. K. |
| Abstract Title: | Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC) |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800497 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.481 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 481 -- Source: Wos |
